Concentration and dose get conflated constantly in this subcategory. Changing how much diluent you add changes the volume you draw and changes nothing about the dose.
0 likes 20mo
Practice · Dosing & titration · continued
Follow-up: Where the four-week escalation interval comes from, and what it is not posts 121–148
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Collapsed as off-topic by two members at trust level 3 or above
Confirming post #122 from a second method, which matters more than confirming it from a second person.
The failure mode on four-week escalation interval is boring rather than dramatic. It is almost always the step everyone assumes was done correctly because it is too simple to get wrong.
I had written a reply contradicting post #120 and deleted it. Here is what survived.
Titrating on tolerability rather than on the calendar: some people escalate when they tolerate a dose well, others escalate on the prescribed schedule regardless. The published trials used a calendar-based schedule. Tolerability-based escalation has no formal evidence base but is not uncommon in practice.
A weak preference rather than a position.
20 likes 20mo
ppm_error, post #96: Worth separating two things that post #92 runs together. Four-week escalation interval would be much easier to settle if anyone reported the denominator. Almost nobody reports the denominator. Go to post
Acknowledging rather than arguing. The reasoning holds as far as I can follow it.
Four-week escalation interval is a question about a distribution, not about a value, and treating it as a value is what produces the confident wrong answers.
0 likes 19mo
Post #126 is right about the mechanism and I think understates the practical bit.
The four-week step is a trial convention, not a pharmacological constant. It is roughly four half-lives for a week-long half-life, which is the interval at which you are assessing a stable concentration rather than a rising one.
This is the version I would want a new member to read first.
5 likes 19mo
I would call the community position on four-week escalation interval likely rather than established, and I would be comfortable defending that hedge.
14 likes 19mo
Narrowing post #126, because the general version has more than one answer.
One more thing on four-week escalation interval that took me far too long to see: the two figures people quote are not measuring the same quantity. Once you notice that, the apparent contradiction disappears.
21 likes 19mo
Collapsed as off-topic by two members at trust level 3 or above
Everything in post #128 holds. The case it does not cover is the one I have.
The four-week escalation interval is a convention from the pivotal trials, not a pharmacological constant. The pharmacological argument is that with a week-long half-life, four weeks approaches steady state and you can assess the dose fairly. That is an argument for not going faster. It is not an argument against going slower.
The number is defensible. The precision I gave it is not.
p.mwangi, post #70: Narrowing post #69, because the general version has more than one answer. My experience of four-week escalation interval contradicts the reply above. I am posting it as a data point rather than as a refutation, because one person's experience is exactly that. Go to post
Saving this. It is the version I will quote when the question comes round again.
d.ndiaye, post #41: The four-week step is a trial convention, not a pharmacological constant. It is roughly four half-lives for a week-long half-life, which is the interval at which you are assessing a stable concentration rather than a rising one. It is the kind of thing that is obvious once and never again. Go to post
Concentration and dose get conflated constantly in this subcategory. Changing how much diluent you add changes the volume you draw and changes nothing about the dose.
It is a small point and it changes the answer, which is an awkward combination.
Collapsed as off-topic by two members at trust level 3 or above
Coming back to post #132, because the follow-up matters more than the original answer.
On four-week escalation interval the community has more anecdote than the confidence in this thread implies, and I include my own contribution in that.
The practical version of four-week escalation interval is three sentences long. The rigorous version is three pages and reaches the same conclusion with the conditions attached.
0 likes 19mo
bench_entry, post #86: Two sentences on four-week escalation interval and then I will stop, because the rest is speculation and the thread is better without mine. What is documented is narrow. What is inferred from it is broad. The gap between them is where every argument here lives. Go to post
Holding at a dose that is working is a legitimate position and it is not what the trial protocols did. The protocols escalated to a target because they were measuring the target dose, not finding each person's minimum.
Not the answer, but possibly the question that gets there.
Taking post #135 at face value and following it one step further.
I would keep four-week escalation interval and the decision it usually gets used for separate in this thread. They are related and they are not the same question, and merging them is why the last one went badly.
19 likes 19mo
Post #135 describes the usual case. This is about the unusual one.
There is no published evidence about slower escalation because nobody studied it. That means the trials support not going faster and are silent on going slower, which is a different claim from "slower is fine".
Small point, but it is the one that usually catches people.
14 likes 19mo
c.dahlberg, post #15: Four-week escalation interval has been discussed here with more heat than it deserves, mostly because two definitions have been in play the whole time. Go to post
Where I would push back on the four-week escalation interval consensus is the confidence, not the direction. The direction looks right. The confidence is borrowed.
b.jankowiak, post #88: Confirming post #87 from a second method, which matters more than confirming it from a second person. There is no published evidence about slower escalation because nobody studied it. That means the trials support not going faster and are silent on going slower, which is a different claim from "slower is fine". The claim is narrower… Go to post
Post #140 answers the question as asked. The question underneath it is different.
Practical note on four-week escalation interval: write down what you expect before you look. The number of times I have found what I went looking for is higher than chance would allow.
Going back down a step is not a failure and the trials allowed it. Several protocols permitted a return to the previous dose for tolerability and then a second attempt at the step.
6 likes 19mo
h.bakker, post #76: Concentration and dose get conflated constantly in this subcategory. Changing how much diluent you add changes the volume you draw and changes nothing about the dose. Go to post
Narrowing post #144, because the general version has more than one answer.
The four-week step is a trial convention, not a pharmacological constant. It is roughly four half-lives for a week-long half-life, which is the interval at which you are assessing a stable concentration rather than a rising one.
Everything in post #142 holds. The case it does not cover is the one I have.
I have three months of notes on four-week escalation interval and the honest summary is that the trend is real and the week-to-week numbers are noise. I nearly drew the opposite conclusion from the first fortnight.
3 likes 19mo
Something worth flagging about four-week escalation interval: the strongest-sounding claims in this thread are the ones with no source attached, which is the usual pattern and not a coincidence.
10 likes 18mo
Suggested topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Where the four-week escalation interval comes from, and what it is not
On the subject in the title: Where the four-week escalation interval comes from, and what it is not Working notes rather than a conclusion. Working notes on four-week escalation interval rather than a…
|
+56 | 60 | 21k | 2y |
|
Holding a dose indefinitely: is there a documented downside?
Holding a dose indefinitely: is there a documented downside? — that is the question, and I have not found it answered plainly anywhere I have looked. I have read the maintained page on this and I still have a…
|
+28 | 32 | 57k | 12mo |
|
Splitting a weekly dose in two: the pharmacokinetic argument against
Splitting a weekly dose in two: the pharmacokinetic argument against — setting out what I have, and where I think it stops being reliable. I have read the maintained page on this and I still have a gap, so I…
|
+24 | 28 | 51k | 5mo |
|
[2026 update] What steady state means for the decision to escalate
The question in the title: What steady state means for the decision to escalate I will give what I have already checked below so nobody repeats it. Asking about steady state directly, because I have read four…
|
+127 | 137 | 32k | 8mo |
|
Titrating on tolerability rather than on the calendar
On the subject in the title: Titrating on tolerability rather than on the calendar Working notes rather than a conclusion. An honest uncertainty about titrating on tolerability rather than a disguised…
|
2 | 31k | 13mo |
Related topics — sharing the tags tirzepatide, dose reduction, worked example
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Multiplicity when you track fifteen variables
Multiplicity when you track fifteen variables — setting out what I have, and where I think it stops being reliable. Asking about multiplicity directly, because I have read four threads on it and each answered…
|
2 | 60k | 11mo | |
|
[2026 update] Dose numbers across compounds are not on the same scale
On the subject in the title: Dose numbers across compounds are not on the same scale Working notes rather than a conclusion. A narrow question about Dose numbers across compounds, deliberately narrow, because…
|
+14 | 18 | 1.2k | 13mo |
|
What a confidence interval means, from scratch — the long version
The question in the title: What a confidence interval means, from scratch — the long version I will give what I have already checked below so nobody repeats it. Asking about confidence interval directly,…
|
+16 | 20 | 2.3k | 8mo |
|
[2026 update] Clearance pathways and what renal impairment changes
On the subject in the title: Clearance pathways and what renal impairment changes Working notes rather than a conclusion. What changes if the standard account of Clearance pathways is wrong? I ask because I…
|
+63 | 69 | 50k | 13mo |
|
Splitting a weekly dose in two: the pharmacokinetic argument against
Splitting a weekly dose in two: the pharmacokinetic argument against — setting out what I have, and where I think it stops being reliable. I have read the maintained page on this and I still have a gap, so I…
|
+24 | 28 | 51k | 5mo |